{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"17"}]}],"title":"Maximum QTcF interval <450 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}]}],"title":"450 ms <=Maximum QTcF interval <480 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"}]}],"title":"480 ms <=Maximum QTcF interval <500 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}],"title":"Maximum QTcF interval ≥500 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"}]}],"title":"QTcF maximum increase from baseline <30 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"}]}],"title":"30 ms <= QTcF maximum increase from baseline <60 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}],"title":"QTcF maximum increase from baseline >=60 ms"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"30"}],"units":"Participants"}],"description":"Number of participants that met categorical criteria of QTcF values in LIC, AML and MDS cohorts","groups":[{"description":"Participants received SC administration of azacitidine daily at a dose of 75 mg/m2/day on Days 1-7 of every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD. In Cycle 1 only, administration of glasdegib commenced on Day 2 of the cycle (C1D2) to permit DDI evaluation.","id":"OG000","title":"Lead-in Cohort"},{"description":"Participants received SC or IV administration of azacitidine at the starting dose of 75 mg/m2/day for 7 days every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD.","id":"OG001","title":"AML Cohort"},{"description":"Participants received SC or IV administration of azacitidine at the starting dose of 75 mg/m2/day for 7 days every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD.","id":"OG002","title":"MDS Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety analysis population included all participants who received at least 1 dose of any study treatment.","reportingStatus":"POSTED","timeFrame":"maximum of approximately 15 months in the LIC cohort, 23 months in AML cohort, and 40 months in MDS cohort","title":"Number of Participants Meeting Categorical Criteria of QTcF Values in LIC, AML and MDS Cohorts","type":"SECONDARY","unitOfMeasure":"Participants"}